Immunomonitoring

OTHER3 trials

Sponsors

University Hospital, Geneva, University Hospital, Grenoble, Central Hospital, Nancy, France

Conditions

Breast CancerCNS Tumor, AdultCandida SepsisCritical IllnessImmunization; SepsisIntra-abdominal InfectionPost-Op Infection

Phase 1

Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma

CompletedNCT01920191

University Hospital, GenevaCNS Tumor, Adult

Start: 2013-08-31End: 2016-03-31Updated: 2016-04-20

Unknown Phase

Feasibility Study on the Characterization of the Immune Profile of Young Patients After Treatment for Breast Cancer

University Hospital, GrenobleBreast Cancer

Start: 2020-06-15End: 2021-11-30Target: 26Updated: 2020-12-07

Innate Immune Response Monitoring Via Monocyte HLA-DR in Severe Intra-abdominal Infections at Risk of Fungal Infection

RecruitingNCT07130799

Central Hospital, Nancy, FranceCandida Sepsis, Critical Illness, Immunization; Sepsis +2

Start: 2025-11-14End: 2027-03-01Target: 100Updated: 2026-02-09

Related Papers

Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.

2023-08-1214 citations

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients

Neuro-Oncology2019-02-08140 citations